Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 21, 2026
TickeronGET DAILY SIGNALS
Axon Enterprise (AXON) Drops -30.7% Over 30 Days as Margin and Dilution Worries Take Hold

Axon Enterprise (AXON) Drops -30.7% Over 30 Days as Margin and Dilution Worries Take Hold

Key Takeaways

  • Axon Enterprise shares declined roughly 30.7% over the past 30 days, from a closing price of $645.72 on August 19, 2026, to $447.76 on September 18, 2026.
  • The selloff followed a strong Q2 2026 earnings report, as investors focused instead on contracting margins, expiring tariff credits, and the removal of cash-flow guidance.
  • A $1 billion zero-coupon convertible note offering announced in mid-September amplified dilution concerns and renewed scrutiny of near-term free cash flow.
  • Despite the pullback, the stock remains modestly higher over the trailing three months, having surrendered gains after an intraday peak of $651.61 on August 19.
  • Rising Treasury yields compounded pressure on a premium valuation that left limited room for execution missteps.

Understanding Axon Enterprise’s Business and Market Position

Axon Enterprise (AXON) stands out as a key player in public safety and law enforcement technology. Its offerings include TASER devices, body-worn cameras, and cloud-based software such as Evidence.com along with the AI Era plan. Recent acquisitions have added counter-drone capabilities via the Dedrone brand, emergency communications through Axon 911, and broader enterprise and federal security solutions.

The company maintains a strong foothold in the U.S. state and local public safety sector, with management estimating about 15% penetration into a roughly $159 billion addressable market. I follow the name closely for its recurring software revenue stream, growing international and enterprise presence, and extended government contracts, while keeping an eye on how its premium valuation stacks up against margin and execution risks.

Stock Performance: The Last 30 Days Compared with the Quarter

Over the most recent 30 days, AXON shares fell about 30.7%, moving from a close of $645.72 on August 19, 2026, to $447.76 on September 18, 2026. The drop picked up speed in September, with the stock sliding roughly 22% as broader pressure hit growth-oriented names.

Looking back over the full quarter, the picture is more mixed. The shares climbed sharply through the summer from around $423 in mid-June to an intraday peak of $651.61 on August 19. Even after the recent decline, the stock sits roughly 5% higher over the trailing three months. On a longer view, shares remain well below the 52-week high of $792.

What Pressured the Stock in the Past Month

The latest leg lower came after the mid-September announcement of a $1 billion zero-coupon convertible senior notes offering due 2031. Shares dropped about 9.8% on the news, ranking among the weakest performers in the S&P 500 that day. The company anticipated roughly $986 million in net proceeds, with about $99.9 million earmarked for capped-call transactions to help contain dilution. Still, the market reacted negatively, viewing the move as a sign of softer near-term cash generation; free cash flow was essentially breakeven in Q2 as inventory was built to meet demand and ease supply-chain concerns.

Those worries echoed themes from the Q2 2026 results released in early August. Revenue came in at about $904 million, up 35% year over year, while annual recurring revenue rose 39% to roughly $1.6 billion and contracted backlog grew 41% to $15.1 billion. Management lifted full-year revenue growth guidance to a 32%–34% range. Yet the shares fell after hours as adjusted gross margin eased from 63.3% to 62.9%, software and services margin declined from 78.9% to 75.1%, and the company withdrew its operating and free cash flow guidance. Management also noted that the third quarter would face higher memory costs and would not benefit from the tariff refunds that supported Q2 results. I checked recent patterns using Tickeron’s AI Pattern Search Engine to see how similar setups have played out.

Broader market conditions added to the pressure. Rising 10-year Treasury yields amid a global bond selloff weighed on high-multiple growth stocks, and AXON’s elevated valuation, which had traded at a premium to peers, offered little buffer.

Performance Drivers Over the Trailing Quarter

Across the past three months, the story centered on solid operational momentum followed by valuation compression. The company posted its tenth straight quarter of revenue growth above 30%, fueled by record TASER 10 demand, a 20% increase in gross bookings, and roughly threefold year-over-year growth in international and enterprise bookings. Analyst support stayed steady, with Barclays lifting its price target to $688, Needham holding at $750, and Argus raising its target to $600; the consensus target remained well above $700.

Even so, the sharp August rally left the stock priced for near-perfect execution. Once margin guidance softened and cash-flow visibility faded, the premium multiple became a drawback. The convertible note offering and higher yields then accelerated the re-rating, even as the underlying business kept expanding.

Key Factors to Monitor Ahead

Several elements are likely to influence AXON near term. The next quarterly report will draw close attention, with consensus estimates pointing to earnings of about $1.94 per share and revenue of roughly $935 million. Focus will center on whether gross margins hold steady amid memory-cost pressures and the lack of tariff credits, and whether free cash flow improves as inventory normalizes.

Progress in newer areas such as the AI Era plan, Dedrone systems, Axon 911, and international and enterprise deployments will also matter. Regulatory views on surveillance and AI tools, municipal budget trends, and the direction of interest rates could affect the valuation multiple. These items should be tracked alongside management’s longer-term goal of roughly $6 billion in annual revenue by 2028.

Exploring AI Tools for Market Context

When reviewing names like this one during periods of volatility, I sometimes turn to Tickeron’s AI Trading Bots for additional perspective on how different strategies are performing across market conditions. The platform’s selection of bots spans various timeframes and approaches, which helps put recent price action into a broader, data-driven frame without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXON

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


AXON's RSI Indicator descends into oversold zone

The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 36.83B. The market cap for tickers in the group ranges from 4.49 to 1.77T. SPCX holds the highest valuation in this group at 1.77T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -16%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was -35%. POWW experienced the highest price growth at 13%, while VWAV experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 41%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 53
Price Growth Rating: 65
SMR Rating: 78
Profit Risk Rating: 79
Seasonality Score: -14 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry AerospaceDefense

Industry
Biotechnology
Address
17800 North 85th Street
Phone
+1 480 991-0797
Employees
6300
Web
https://www.axon.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.